Individually Optimized Contrast-Enhancement 4D-CT for Pancreatic Adenocarcinoma in Radiotherapy Simulation
Compared with current clinical practice, the individually optimized CE 4D-CT can potentially
provide much improved tumor-to-parenchyma conspicuity of pancreatic adenocarcinoma. This
will help the radiation oncologists or radiologists to contour the tumor with higher
precision and confidence, and compute the tumor volume and tumor motion more accurately.
1. Patients 18 years old or older
2. Patients with PDA who have not had surgical removal of their tumor and who are
planned for treatment with radiotherapy in the Radiation Oncology Department at the
University of Maryland.
3. Patients who have signed the contrast consent form and have been recommended by
physicians to have contrast-enhanced CT scans.
4. Patients who have signed the consent form for this study
1. Pregnant or breast-feeding women.
2. Patients with severely decreased renal function19-21.
3. Patients with known severe allergic reactions to contrast.
4. Patients who have difficulty lying flat on their back for extended periods of time.
5. Patients with breaths per minute (BPM) rate less than 10, due to the limitation of
4D-CT image reconstruction software.
Type of Study:
Observational Model: Case-Only, Time Perspective: Prospective
Primary Objective Analysis
First, experienced radiologists or radiation oncologists specialized in gastrointestinal (GI)/pancreas disease will score the CT images by a qualitative evaluation of:
(1) General image quality, in terms of anatomical details, motion artifacts and beam hardening;
Outcome Time Frame:
Wei Lu, Ph. D., DABR
United States: Institutional Review Board
- Pancreatic Adenocarcinoma
- Contrast Enhanced CT
- Radiotherapy Simulation
- Adenocarcinoma, Mucinous
||Baltimore, Maryland 21201